



AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Reply to: Oncologic thoracic surgery during the second wave of COVID-19 pandemic: How to be ready for the storm

This is a pre print version of the following article:			
Original Citation:			
Availability:			
This version is available	http://hdl.handle.net/2318/1805311	since 2021-09	-26T16:48:52Z
Published version:			
DOI:10.1002/jso.26334			
Terms of use:			
Open Access			
Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works			
requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.			

(Article begins on next page)

1

Reply to: Oncologic thoracic surgery during the second wave of COVID-19

pandemic: how to be ready for the storm

Elena Vissio¹ M.D., Enrico Costantino Falco¹ M.D., Giammarco Collemi¹ B.S., Fulvio Borella² M.D., Mauro

Papotti³ M.D., Antonio Scarmozzino⁴ M.D., Paola Cassoni¹ M.D. Ph.D., Luca Bertero¹ M.D. Ph.D.

1: Pathology Unit, Department of Medical Sciences, University of Turin and "Città della Salute e

della Scienza di Torino" University Hospital, Turin, Italy

2: Obstetrics and Gynecology 1U, Department of Surgical Sciences, Sant'Anna Hospital, University

of Turin and "Città della Salute e della Scienza di Torino" University Hospital, Turin, Italy

3: Pathology Unit, Department of Oncology, University of Turin and "Città della Salute e della

Scienza di Torino" University Hospital, Turin, Italy

4: Healthcare Management, "Città della Salute e della Scienza di Torino" University Hospital, Turin,

Italy

Corresponding author:

Prof. Paola Cassoni

Pathology Unit, Department of Medical Sciences

Via Santena 7

10126 Torino, Italy

E-mail: paola.cassoni@unito.it

Phone: +390116334272

Fax: +390116635267

Running head: COVID-19 impact on surgical oncology

Category: Reply to Letter to the Editor

Dear Editor,

We would like to thank Gallina et al. for their letter and appreciation of our manuscript.[1] Indeed, our aim was both to report our specific data while also eliciting the experiences of other centers and groups.

Our study,[2] arising from the point of view of a Pathology unit, allowed us to evaluate the comprehensive surgical oncology activity of our Institution, but it is really interesting to read about the other side of the coin: how it was possible from a clinical point of view to preserve the quality and quantity of surgical procedures despite the COVID-19 pandemic. A report from a Thoracic Surgery division is especially relevant considering the potential consequences of a SARS-CoV-2 infection in these fragile patients.

These suggestions will hopefully help address the present new wave of infections[3] and we think this is a critical issue. Considered that for the foreseeable future we will have to deal with intermittent lockdowns and ongoing limitations affecting multiple healthcare activities (e.g., elective surgery, outpatient practice,...), it will be extremely important to safeguard cancer care starting from preserving screening protocols and prompt diagnostic/therapeutic procedures. Their interruptions or even delays can lead to severe consequences in the coming years for both patients' outcomes and financial sustainability.[4, 5]

Regarding future research outlooks, it will be important to comprehensively evaluate the overall consequences of the COVID-19 pandemic on surgical oncology practice, also to estimate its potential impact on cancer care in the coming years and design possible coping strategies.

Conflict of Interest

The authors declare they have no conflict of interest.

Authors provide the permission to publish this letter.

References

- [1] F.T. Gallina, E. Melis, E. Mercadante, G. Alessandrini, D. Forcella, V. Cerasoli, F. Corzani, L. Mosillo, F. Facciolo, Oncologic thoracic surgery during the second wave of COVID-19 pandemic: how to be ready for the storm, J. Surg. Oncol. (2020).
- [2] E. Vissio, E.C. Falco, G. Collemi, F. Borella, M. Papotti, A. Scarmozzino, P. Cassoni, L. Bertero, Impact of COVID-19 lockdown measures on oncological surgical activity: Analysis of the surgical pathology caseload of a tertiary referral hospital in Northwestern Italy, J. Surg. Oncol. (2020).
- [3] M.K. Looi, Covid-19: Is a second wave hitting Europe?, BMJ 371 (2020) m4113.
- [4] J.H. Yong, J.G. Mainprize, M.J. Yaffe, Y. Ruan, A.E. Poirier, A. Coldman, C. Nadeau, N. Iragorri, R.J. Hilsden, D.R. Brenner, The impact of episodic screening interruption: COVID-19 and population-based cancer screening in Canada, J. Med. Screen. (2020) 969141320974711.
- [5] L.Y.W. Lee, J.B. Cazier, T. Starkey, S.E.W. Briggs, R. Arnold, V. Bisht, S. Booth, N.A. Campton, V.W.T. Cheng, G. Collins, H.M. Curley, P. Earwaker, M.W. Fittall, S. Gennatas, A. Goel, S. Hartley, D.J. Hughes, D. Kerr, A.J.X. Lee, R.J. Lee, S.M. Lee, H. McKenzie, C.P. Middleton, N. Murugaesu, T. Newsom-Davis, A.C. Olsson-Brown, C. Palles, T. Powles, E.A. Protheroe, K. Purshouse, A. Sharma-Oates, S. Sivakumar, A.J. Smith, O. Topping, C.D. Turnbull, C. Varnai, A.D.M. Briggs, G. Middleton, R. Kerr, U.K.C.C.M.P. Team, COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study, Lancet Oncol. 21(10) (2020) 1309-1316.